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The use of immunosuppressive therapies, including certain common synthetic disease-modifying antirheumatic drugs (csDMARDs), targeted synthetic DMARDs (tsDMARDs) and biologics, has improved disease control and quality of life for patients with autoimmune and inflammatory diseases. However, as these treatments may attenuate protective immunity, some patients are potentially at an increased risk of developing common and opportunistic infections, complicated by higher rates of related morbidity and mortality than age- and sex-matched control populations ([@CIT0001]). Although this risk can be significantly reduced with commercially available vaccines, physicians often hesitate to vaccinate these patients due to uncertainties regarding the safety and efficacy of immunization while on immunosuppressive medications ([@CIT0005]).

This executive summary of the clinical recommendations provides guidance regarding the vaccination of adults receiving immunosuppressive medications for the treatment of IMDs or infants with intrauterine exposure to such agents.

MATERIALS AND METHODS {#s1}
=====================

A Canadian multidisciplinary committee with expertise in gastroenterology (JKM, AB, BB, AHS), dermatology (KAP, MG, RB, VH), rheumatology (BH, JEP, JW, SJ) and infectious diseases (DK, DCV) developed guidelines on the management of vaccination in patients on immunosuppressive therapies. Literature searches by Synapse Medical Communications identified clinical trials, meta-analyses, systematic reviews, observational studies, case series and existing guidelines published from 2009 to 2017 across multiple databases (Embase, MEDLINE, PubMed) as per the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system ([@CIT0010]). Reference lists were manually searched to identify relevant articles and were included based on the committee's discretion. Published studies were then reviewed by the committee and assessed according to GRADE evidence levels ([@CIT0010]). The quality of evidence was rated as 'high' (indicating that further research is unlikely to change the confidence in the estimate of effect), 'moderate' (implying that further research is likely to have an impact on the confidence in the estimate of effect), 'low' (suggesting that further research is likely to have a strong impact on the confidence in the estimate of effect), or 'very low' (meaning that any estimate of effect is very uncertain).

The steering committee (KAP \[chair\], JKM, DK, BH) developed the initial statements, which underwent two rounds of revisions according to feedback received from all authors. All 14 members voted on a web-based platform to determine the level of agreement for each statement using a five-point scale ('strongly agree', 'agree', 'neutral', 'disagree', 'strongly disagree'). Statements achieving ≥75% agreement were included in the guidelines. Of the 15 statements considered, two statements were rejected.

The strength of recommendations was evaluated according to GRADE and rated as 'strong' when desirable consequences clearly outweighed undesirable consequences, 'conditional' when desirable consequences probably outweighed undesirable consequences, or 'weak' when the balance between desirable and undesirable consequences was closely balanced or uncertain.

RESULTS {#s2}
=======

The guidelines developed consist of 13 statements addressing general immunization strategies for individuals exposed to biologic or nonbiologic immunosuppressive agents ([Table 1](#T1){ref-type="table"}) ([@CIT0011]). Of these, 10 statements focus on the management of adults with IMDs who are considering age-appropriate primary and secondary immunizations with live or inactivated vaccines. Recommendations specifically regarding the use of the live attenuated herpes zoster vaccine are also provided. The remaining three statements pertain to the timing of routine childhood vaccinations in infants exposed to immunosuppressive drugs either in utero during the third trimester or through breastfeeding.

###### 

Guideline statements\*

                                                                               Recommendation                                                                                                                                                                                                                                                                                                                                                                 Evidence level/Recommendation strength
  ---------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------
  Statement 1                                                                  In patients newly diagnosed with immune-mediated diseases, we recommend that immunization status be assessed, and age- and condition-appropriate vaccines be administered prior to initiation of immunosuppressive treatment.                                                                                                                                                  strong recommendation, moderate-level evidence
  **Inactivated vaccines**                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Statement 2a                                                                 To optimize the immunogenicity of inactivated vaccines in treatment-naïve patients with immune-mediated conditions, we suggest that immunization be performed at least 2 weeks prior to initiation of immunosuppressive therapy, whenever possible.                                                                                                                            conditional recommendation, moderate-level evidence
  Statement 2b                                                                 Among patients with immune-mediated diseases currently receiving immunosuppression, we recommend that immunosuppressive treatment not be interrupted for administration of inactivated vaccines.                                                                                                                                                                               strong recommendation, moderate-level evidence
  Statement 2c                                                                 In patients with immune-mediated diseases treated with rituximab who require optimal vaccine immunogenicity, we recommend that immunization be deferred to ≥5 months after the last dose and at least 4 weeks prior to the subsequent dose of rituximab.                                                                                                                       strong recommendation, low-level evidence
  **Live attenuated herpes zoster vaccine** ^**†**^                                                                                                                                                                                                                                                                                                                                                                                                           
  Statement 3a                                                                 To optimize the immunogenicity of the live attenuated herpes zoster vaccine in treatment-naïve patients with immune-mediated conditions, we suggest immunization be performed at least 2--4 weeks prior to initiation of immunosuppressive therapy.                                                                                                                            conditional recommendation, moderate-level evidence
  Statement 3b                                                                 In patients with immune-mediated diseases on immunosuppressive agents, the live attenuated herpes zoster vaccine can be safely administered to patients at risk, but the subunit vaccine is the preferred alternative. Individual situations should be assessed for patients treated with a combination of immunosuppressive drugs, if the live vaccine is being considered.   strong recommendation, moderate-level evidence
  **Other live attenuated vaccines**                                                                                                                                                                                                                                                                                                                                                                                                                          
  Statement 4a                                                                 In treatment-naïve patients with immune-mediated diseases who are vaccinated with live attenuated vaccines, we recommend that the duration of viremia following immunization be considered when determining the optimal time to initiate immunosuppressive therapy.                                                                                                            strong recommendation, very low-level evidence
  Statement 4b                                                                 In patients with immune-mediated diseases who interrupt immunosuppressive treatment prior to vaccination, we recommend that the duration of viremia following immunization be considered when determining the optimal time to re-initiate immunosuppressive therapy.                                                                                                           strong recommendation, very low-level evidence
  Statement 4c                                                                 In patients with immune-mediated diseases on immunosuppressive agents, we suggest that live attenuated vaccines be administered when individual benefits outweigh the perceived risks.                                                                                                                                                                                         conditional recommendation, low-level evidence
  Statement 4d                                                                 In situations where patient safety is a paramount concern and the clinical situation allows, we suggest that immunosuppressive treatment be interrupted for a duration based on drug pharmacokinetics prior to immunization with live vaccines.                                                                                                                                conditional recommendation, low-level evidence
  **Vaccination of infants with early exposure to immunosuppressive agents**                                                                                                                                                                                                                                                                                                                                                                                  
  Statement 5a                                                                 In infants exposed to immunosuppressive agents in utero during the 3rd trimester, we recommend that inactivated vaccines be administered according to the local immunization schedule.                                                                                                                                                                                         strong recommendation, very low-level evidence
  Statement 5b                                                                 In infants exposed to immunosuppressive agents in utero during the 3rd trimester, we recommend that the MMR and varicella vaccines be administered according to the local immunization schedule.                                                                                                                                                                               strong recommendation, low-level evidence
  Statement 5c                                                                 In infants breast-fed by mothers on immunosuppressive regimens, we recommend that inactivated and live attenuated vaccines be administered according to the local immunization schedule without delay.                                                                                                                                                                         strong recommendation, very low-level evidence

MMR: measles, mumps, rubella

\*Please refer to the full guidelines for further information.

†The Centers for Disease Control and Prevention (CDC) recommends the use of the herpes zoster subunit vaccine over the live attenuated version ([@CIT0011]).

In the full guideline document, each statement is followed by a discussion of the supporting evidence, including the role that biologic and nonbiologic agents may play in supporting these statements ([@CIT0011]). Any existing recommendations or guidance from other physician organizations or societies is also discussed ([@CIT0011]).

DISCUSSION {#s3}
==========

This document is intended to provide guidance on the vaccination of individuals exposed to immunosuppressive therapies. For an in-depth review of the data and its relevance to individual medical specialities, readers are directed to the full guideline document ([@CIT0011]).

While specialists endorse the importance of giving age- and disease-appropriate vaccines to patients with IMDs, primary care physicians (PCPs) are often tasked with carrying out immunizations in these patients. To ensure that necessary vaccines are given and that patients receive consistent care across health care providers, communication between specialists and PCPs is imperative. Should the need arise, these guidelines may serve to inform not only specialists but also family physicians and other health care providers on issues regarding the safety and efficacy of vaccines in patients with IMDs on immunosuppressive therapies.

Although these guidelines were developed according to the best data available to date, the body of evidence regarding the safety and efficacy of vaccination in this patient population remains scarce and incomplete. Therefore, clinical judgment based on a careful assessment of patient factors and the risks and benefits of vaccination should always prevail when determining the best course of action for each individual.

Regular updates to the current guidelines will be necessary as new clinical trial data and treatment options emerge.
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